| Gene Symbol | FLOT1 |
| Full Name | Flotillin 1 |
| Chromosome | 6p21.3 |
| Protein Type | Structural Protein |
| Target Class | Structural Protein |
| Function | FLOT1 performs essential cellular functions |
| Mechanism of Action | Drug candidates would modulate FLOT1-mediated lipid raft organization and signaling platform assembly, thereby disrupting pathological protein trafficking and reducing amyloid-beta or tau-related pathology in neurodegenerative diseases. FLOT1 inhibitors would interfere with membrane scaffold formation necessary for aberrant signaling in neuroinflammatory and proteinopathic cascades. |
| Primary Expression | activated microglia) |
| Druggability | Low (0.35) |
| Clinical Stage | Phase II |
| Molecular Weight | 47 kDa |
| Amino Acids | 427 aa |
| Pathways | Mitochondrial Function, cholesterol secretion, endocytosis, epithelial-mesenchymal transition, glioblastoma cell invasion |
| UniProt ID | O75955 |
| NCBI Gene ID | 10211 |
| Ensembl ID | ENSG00000231768 |
| OMIM | 606823 |
| GeneCards | FLOT1 |
| Human Protein Atlas | FLOT1 |
| Associated Diseases | ALS, Alzheimer'S Disease, CANCER |
| Known Drugs/Compounds | Methyl-beta-cyclodextrin, Filipin III, Dynasore, FLT1-targeting antisense oligonucleotide (investigational) |
| Interactions | P38, TAU, Rb, GBM, TNF, SDC1 |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Flotillin-1 Stabilization Compounds |
| KG Connections | 306 knowledge graph edges |
| Databases | GeneCardsHPASTRING |